What: As there are few means of preventing or early screening for most blood cancers, the LLS research
agenda is focused on finding cures. LLS drives research in areas of unmet medical need, and helps to bridge
the gap between academic discovery and drug development. LLS identifies and funds the most promising
blood cancer research projects around the world, and forges partnerships with academic institutions,
biotechnology and pharmaceutical companies to accelerate the development of new therapies.
Why: LLS’s investment in research has played a critical role in advancing many of today’s life-saving
therapies for blood cancer patients.
Since LLS first started investing in research more than 60 years ago, cures for many patients with acute
lymphocytic leukemia (ALL) and Hodgkin lymphoma have been achieved.
Survival rates for many blood cancer patients have doubled, tripled and even quadrupled since 1960.
From 2001 through 2013, nearly 40% of new anti-cancer treatments were FDA-approved for blood cancer
patients, more first approvals than for any other group of cancer patients.
LLS research grants have funded many important advances, including targeted and immunotherapies. Some
therapies LLS helped advance include imatinib, bortezomib, lenalidomide, rituximab and ibrutinib.
P.S. Don’t forget to donate to the cause: http://pages.teamintraining.org/gba/nikesf14/ashbo